Warren Wise Reveals the Secrets in Qiagen’s DNA

• Qiagen generates more than USD 2 billion in annual revenue, approximately 90% of which is recurring due to long-term consumables demand from installed laboratory equipment.
• In fiscal 2025, Qiagen produced around USD 450 million in free cash flow, exceeding reported net income, while net debt remained below one year’s EBITDA.
• The company targets growth in five product areas—from roughly USD 1.5 billion to USD 2 billion in combined revenue by 2028, nearly twice the expected market growth rate.
• Warren Wise raised concerns about declining R&D investment, a lower share of employees in research and development, and the dissolution of Qiagen’s Science Committee.
• Qiagen’s reported near-fourfold rise in operating profit was partly distorted by exceptional charges in the prior year; on an adjusted basis, the increase was only slightly above USD 50 million.
• Warren Wise awarded Qiagen a score of 4 out of 5, describing its equity story as convincing but vulnerable; Jonathan Pratt became CEO on September 1, 2026, amid a strategic review and reported takeover interest.

Jetzt bis zu 120 € Prämie sichern! Egal ob Trading, Sparen oder beides - bei SMARTBROKER+ ist für alle was dabei. Eröffnen Sie ein Depot bei Smartbroker+ und erhalten als Prämie jetzt bis zu 120 €!

Schreibe Deinen Kommentar